Follow-Up of Pulmonary Hypertension With Echocardiography

JACC: Cardiovascular Imaging

Volumn 9, Issue 6, 2016, Pages 733-746

  Wright, Leah M ^a,b,c   Dwyer, Nathan ^b   Celermajer, David ^d   Kritharides, Len ^d   Marwick, Thomas H ^a,b,c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b ROYAL HOBART HOSPITAL   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

echocardiography; follow up; magnetic resonance imaging; pulmonary hypertension; RV function

Indexed keywords

BIOLOGICAL MARKER;

ATRIAL SIZE; CARDIOVASCULAR PARAMETERS; ECHOCARDIOGRAPHY; FOLLOW UP; HEART AFTERLOAD; HEART PERFORMANCE; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE ISOVOLUMIC ACCELERATION; HEART RIGHT VENTRICLE THICKNESS; HEART VENTRICLE SIZE; HEMODYNAMICS; HUMAN; LUNG VASCULAR RESISTANCE; META ANALYSIS (TOPIC); MUSCLE STRAIN; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SYSTOLIC BLOOD PRESSURE; TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION; ARTERIAL PRESSURE; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DOPPLER ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HYPERTENSION, PULMONARY; MORTALITY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

ARTERIAL PRESSURE; ECHOCARDIOGRAPHY, DOPPLER; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; IMAGE INTERPRETATION, COMPUTER-ASSISTED; PREDICTIVE VALUE OF TESTS; PULMONARY ARTERY; RISK FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 84978217256     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2016.02.022     Document Type: Review

References (70)

1. 1 McLaughlin, V.V., Sitbon, O., Badesch, D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005), 244–249.
2. 2 Gabler, N.B., French, B., Strom, B.L., et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 141 (2012), 20–26.
3. 3 Ling, Y., Johnson, M.K., Kiely, D.G., et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 186 (2012), 790–796.
4. 4 McLaughlin, V.V., Badesch, D.B., Delcroix, M., et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 54 (2009), S97–S107.
5. 5 Galie, N., Hoeper, M.M., Humbert, M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 30 (2009), 2493–2537.
6. 6 Raymond, R.J., Hinderliter, A.L., Willis, P.W., et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39 (2002), 1214–1219.
7. 7 Montani, D., Savale, L., Natali, D., et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 31 (2010), 1898–1907.
8. 8 Brittain, E.L., Pugh, M.E., Wheeler, L.A., et al. Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. J Am Coll Cardiol HF 1 (2013), 300–307.
9. 9 Channick, R.N., Simonneau, G., Sitbon, O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001), 1119–1123.
10. 10 Humbert, M., Barst, R.J., Robbins, I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004), 353–359.
11. 11 Galie, N., Rubin, L., Hoeper, M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371 (2008), 2093–2100.
12. 12 Sastry, B.K., Narasimhan, C., Reddy, N.K., Raju, B.S., Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43 (2004), 1149–1153.
13. 13 Singh, T.P., Rohit, M., Grover, A., Malhotra, S., Vijayvergiya, R., A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151 (2006), 851.e1–851.e5.
14. 14 Badesch, D.B., Champion, H.C., Sanchez, M.A., et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54 (2009), S55–S66.
15. 15 Lafitte, S., Pillois, X., Reant, P., et al. Estimation of pulmonary pressures and diagnosis of pulmonary hypertension by Doppler echocardiography: a retrospective comparison of routine echocardiography and invasive hemodynamics. J Am Soc Echocardiogr 26 (2013), 457–463.
16. 16 Fisher, M.R., Forfia, P.R., Chamera, E., et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179 (2009), 615–621.
17. 17 D'Alto, M., Romeo, E., Argiento, P., et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol 168 (2013), 4058–4062.
18. 18 Greiner, S., Jud, A., Aurich, M., et al. Reliability of noninvasive assessment of systolic pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: analysis in a large patient population. J Am Heart Assoc, 3, 2014, e001103.
19. 19 Galie, N., Hinderliter, A.L., Torbicki, A., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003), 1380–1386.
20. 20 Granstam, S.O., Bjorklund, E., Wikstrom, G., Roos, M.W., Use of echocardiographic pulmonary acceleration time and estimated vascular resistance for the evaluation of possible pulmonary hypertension. Cardiovasc Ultrasound, 11, 2013, 7.
21. 21 Tossavainen, E., Soderberg, S., Gronlund, C., Gonzalez, M., Henein, M.Y., Lindqvist, P., Pulmonary artery acceleration time in identifying pulmonary hypertension patients with raised pulmonary vascular resistance. Eur Heart J Cardiovasc Imaging 14 (2013), 890–897.
22. 22 Arkles, J.S., Opotowsky, A.R., Ojeda, J., et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med 183 (2011), 268–276.
23. 23 Abbas, A.E., Fortuin, F.D., Schiller, N.B., Appleton, C.P., Moreno, C.A., Lester, S.J., Echocardiographic determination of mean pulmonary artery pressure. Am J Cardiol 92 (2003), 1373–1376.
24. 24 Pyxaras, S.A., Pinamonti, B., Barbati, G., et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. Eur J Echocardiogr 12 (2011), 696–701.
25. 25 Ristow, B., Ali, S., Ren, X., Whooley, M.A., Schiller, N.B., Elevated pulmonary artery pressure by Doppler echocardiography predicts hospitalization for heart failure and mortality in ambulatory stable coronary artery disease: the Heart and Soul Study. J Am Coll Cardiol 49 (2007), 43–49.
26. 26 Forfia, P.R., Fisher, M.R., Mathai, S.C., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174 (2006), 1034–1041.
27. 27 Rudski, L.G., Lai, W.W., Afilalo, J., et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr 23 (2010), 685–713 quiz 786–8.
28. 28 Nagueh, S.F., Kopelen, H.A., Zoghbi, W.A., Relation of mean right atrial pressure to echocardiographic and Doppler parameters of right atrial and right ventricular function. Circulation 93 (1996), 1160–1169.
29. 29 Abbas, A.E., Fortuin, F.D., Schiller, N.B., Appleton, C.P., Moreno, C.A., Lester, S.J., A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 41 (2003), 1021–1027.
30. 30 Dahiya, A., Vollbon, W., Jellis, C., Prior, D., Wahi, S., Marwick, T., Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. Heart 96 (2010), 2005–2009.
31. 31 Abbas, A.E., Franey, L.M., Marwick, T., et al. Noninvasive assessment of pulmonary vascular resistance by Doppler echocardiography. J Am Soc Echocardiogr 26 (2013), 1170–1177.
32. 32 Tonelli, A.R., Conci, D., Tamarappoo, B.K., Newman, J., Dweik, R.A., Prognostic value of echocardiographic changes in patients with pulmonary arterial hypertension receiving parenteral prostacyclin therapy. J Am Soc Echocardiogr 27 (2014), 733–741.e2.
33. 33 Kusunose, K., Tsutsui, R.S., Bhatt, K., et al. Prognostic value of RV function before and after lung transplantation. J Am Coll Cardiol Img 7 (2014), 1084–1094.
34. 34 Addetia, K., Bhave, N.M., Tabit, C.E., et al. Sample size and cost analysis for pulmonary arterial hypertension drug trials using various imaging modalities to assess right ventricular size and function end points. Circ Cardiovasc Imaging 7 (2014), 115–124.
35. 35 Peacock, A.J., Crawley, S., McLure, L., et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. Circ Cardiovasc Imaging 7 (2014), 107–114.
36. 36 van Wolferen, S.A., Marcus, J.T., Boonstra, A., et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 28 (2007), 1250–1257.
37. 37 McCrory, D.C., Coeytaux, R.R., Schmit, K.M., et al. Pulmonary Arterial Hypertension: Screening, Management, and Treatment. 2013, Agency for Healthcare Research and Quality, Rockville, MD.
38. 38 Fijalkowska, A., Kurzyna, M., Torbicki, A., et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129 (2006), 1313–1321.
39. 39 Eysmann, S.B., Palevsky, H.I., Reichek, N., Hackney, K., Douglas, P.S., Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 80 (1989), 353–360.
40. 40 Hinderliter, A.L., Willis, P.W. 4th, Barst, R.J., et al., Primary Pulmonary Hypertension Study Group. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 95 (1997), 1479–1486.
41. 41 Sano, H., Tanaka, H., Motoji, Y., et al. Right ventricular function and right-heart echocardiographic response to therapy predict long-term outcome in patients with pulmonary hypertension. Can J Cardiol 31 (2015), 529–536.
42. 42 Ghio, S., Pazzano, A.S., Klersy, C., et al. Clinical and prognostic relevance of echocardiographic evaluation of right ventricular geometry in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol 107 (2011), 628–632.
43. 43 Morishita, T., Miyaji, K., Akao, I., et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. J Med Ultrason 36 (2009), 201–206.
44. 44 Brierre, G., Blot-Souletie, N., Degano, B., Tetu, L., Bongard, V., Carrie, D., New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. Eur J Echocardiogr 11 (2010), 516–522.
45. 45 Nagaya, N., Nishikimi, T., Uematsu, M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000), 865–870.
46. 46 Grapsa, J., O'Regan, D.P., Pavlopoulos, H., Durighel, G., Dawson, D., Nihoyannopoulos, P., Right ventricular remodelling in pulmonary arterial hypertension with three-dimensional echocardiography: comparison with cardiac magnetic resonance imaging. Eur J Echocardiogr 11 (2010), 64–73.
47. 47 Wilkins, M.R., Paul, G.A., Strange, J.W., et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 171 (2005), 1292–1297.
48. 48 Lang, R.M., Badano, L.P., Mor-Avi, V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16 (2015), 233–270.
49. 49 Yeo, T.C., Dujardin, K.S., Tei, C., Mahoney, D.W., McGoon, M.D., Seward, J.B., Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81 (1998), 1157–1161.
50. 50 Mahapatra, S., Nishimura, R.A., Oh, J.K., McGoon, M.D., The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr 19 (2006), 1045–1050.
51. 51 Yoshifuku, S., Otsuji, Y., Takasaki, K., et al. Pseudonormalized Doppler total ejection isovolume (Tei) index in patients with right ventricular acute myocardial infarction. Am J Cardiol 91 (2003), 527–531.
52. 52 Badesch, D.B., Abman, S.H., Simonneau, G., Rubin, L.J., McLaughlin, V.V., Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007), 1917–1928.
53. 53 Sebbag, I., Rudski, L.G., Therrien, J., Hirsch, A., Langleben, D., Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. Am J Cardiol 88 (2001), 1060–1063.
54. 54 Borges, A.C., Knebel, F., Eddicks, S., et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. Am J Cardiol 98 (2006), 530–534.
55. 55 Mathai, S.C., Sibley, C.T., Forfia, P.R., et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol 38 (2011), 2410–2418.
56. 56 Schattke, S., Knebel, F., Grohmann, A., et al. Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler Tissue and Speckle Tracking echocardiography study. Cardiovasc Ultrasound, 8, 2010, 3.
57. 57 Vogel, M., Schmidt, M.R., Kristiansen, S.B., et al. Validation of myocardial acceleration during isovolumic contraction as a novel noninvasive index of right ventricular contractility: comparison with ventricular pressure-volume relations in an animal model. Circulation 105 (2002), 1693–1699.
58. 58 Stanton, T., Leano, R., Marwick, T.H., Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circulation Cardiovascular imaging 2 (2009), 356–364.
59. 59 Freed, B.H., Tsang, W., Bhave, N.M., et al. Right ventricular strain in pulmonary arterial hypertension: a 2D echocardiography and cardiac magnetic resonance study. Echocardiography 32 (2015), 257–263.
60. 60 Fine, N.M., Chen, L., Bastiansen, P.M., et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circulation Cardiovascular imaging 6 (2013), 711–721.
61. 61 Sachdev, A., Villarraga, H.R., Frantz, R.P., et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest 139 (2011), 1299–1309.
62. 62 Portnoy, S.G., Rudski, L.G., Echocardiographic evaluation of the right ventricle: a 2014 perspective. Curr Cardiol Rep, 17, 2015, 21.
63. 63 Bustamante-Labarta, M., Perrone, S., De La Fuente, R.L., et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr 15 (2002), 1160–1164.
64. 64 Naeije, R., Manes, A., The right ventricle in pulmonary arterial hypertension. Eur Respir Rev 23 (2014), 476–487.
65. 65 Vanderpool, R.R., Pinsky, M.R., Naeije, R., et al. RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension. Heart 101 (2015), 37–43.
66. 66 Brown, K.A., Ditchey, R.V., Human right ventricular end-systolic pressure-volume relation defined by maximal elastance. Circulation 78 (1988), 81–91.
67. 67 Kuehne, T., Yilmaz, S., Steendijk, P., et al. Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension. Circulation 110 (2004), 2010–2016.
68. 68 Sanz, J., Garcia-Alvarez, A., Fernandez-Friera, L., et al. Right ventriculo-arterial coupling in pulmonary hypertension: a magnetic resonance study. Heart 98 (2012), 238–243.
69. 69 Knight, D.S., Grasso, A.E., Quail, M.A., et al. Accuracy and reproducibility of right ventricular quantification in patients with pressure and volume overload using single-beat three-dimensional echocardiography. J Am Soc Echocardiogr 28 (2015), 363–374.
70. 70 Ling, L.F., Marwick, T.H., Echocardiographic assessment of right ventricular function: how to account for tricuspid regurgitation and pulmonary hypertension. J Am Coll Cardiol Img 5 (2012), 747–753.